AIMC Topic: Non-alcoholic Fatty Liver Disease

Clear Filters Showing 21 to 30 of 139 articles

Machine learning-based integration reveals reliable biomarkers and potential mechanisms of NASH progression to fibrosis.

Scientific reports
Non-alcoholic fatty liver disease (NAFLD) affects about 25% of adults worldwide. Its advanced form, non-alcoholic steatohepatitis (NASH), is a major cause of liver fibrosis, but there are no non-invasive tests for diagnosing or preventing it. In our ...

Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study.

Phytomedicine : international journal of phytotherapy and phytopharmacology
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health concern worldwide, exhibiting an increasing incidence that necessitates immediate intervention. Epigallocatechin-3-gallate (EGCG) has shown significant pharmaco...

Automated Whole-Liver Fat Quantification with Magnetic Resonance Imaging-Derived Proton Density Fat Fraction Map: A Prospective Study in Taiwan.

Gut and liver
BACKGROUND/AIMS: Magnetic resonance imaging (MRI) with a proton density fat fraction (PDFF) sequence is the most accurate, noninvasive method for assessing hepatic steatosis. However, manual measurement on the PDFF map is time-consuming. This study a...

Identification of CACNB1 protein as an actionable therapeutic target for hepatocellular carcinoma via metabolic dysfunction analysis in liver diseases: An integrated bioinformatics and machine learning approach for precise therapy.

International journal of biological macromolecules
In addition to histological evaluation for nonalcoholic fatty liver disease (NAFLD), a comprehensive analysis of the metabolic landscape is urgently needed to categorize patients into distinct subgroups for precise treatment. In this study, a total o...

Life's Crucial 9 and NAFLD from association to SHAP-interpreted machine learning predictions.

Scientific reports
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. Cardiovascular disease (CVD) and NAFLD share multiple common risk factors. Life's Crucial 9 (LC9), a novel indicator for comprehensive assessment of card...

Machine learning for predicting metabolic-associated fatty liver disease including NHHR: a cross-sectional NHANES study.

PloS one
OBJECTIVE: Metabolic - associated fatty liver disease (MAFLD) is a common hepatic disorder with increasing prevalence, and early detection remains inadequately achieved. This study aims to explore the relationship between the non-high-density lipopro...

Biological age prediction and NAFLD risk assessment: a machine learning model based on a multicenter population in Nanchang, Jiangxi, China.

BMC gastroenterology
BACKGROUND: The objective was to develop a biological age prediction model (NC-BA) for the Chinese population to enrich the relevant studies in this population. And to investigate the association between accelerated age and NAFLD.

Detecting severe coronary artery stenosis in T2DM patients with NAFLD using cardiac fat radiomics-based machine learning.

Scientific reports
To analyze radiomics features of cardiac adipose tissue in individuals with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD), integrating relevant clinical indicators, and employing machine learning techniques to construct a preci...

FibrAIm - The machine learning approach to identify the early stage of liver fibrosis and steatosis.

International journal of medical informatics
BACKGROUND: Early recognition of steatosis (fatty liver) and fibrosis in liver health is crucial for effectively managing and preventing the possibility of liver dysfunction. Detecting steatosis helps identify individuals at risk of liver-related dis...

Unveiling NLR pathway signatures: EP300 and CPN60 markers integrated with clinical data and machine learning for precision NASH diagnosis.

Cytokine
BACKGROUND: Given the increasing prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH), there is a critical need for accurate non-invasive early diagnostic markers.